Torch Biosciences
- Company typePrivate
- Founded2016
- HeadquartersNew York, United States
- Headcount—
- GTM typeB2B
- OfferingSoftware
Torch Biosciences firmographics
Firmographics- Name
- Torch Biosciences
- Legal name
- Torch Bio
- Website
- https://sites.google.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Ownership category
- akta.pro rank
Torch Biosciences industry classification
Industry- Product category
- AI Drug Safety Prediction
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
- akta.pro primary industry
- In Silico / Computational Toxicology & PK/PD Modeling (HLAGAFAM)
- akta.pro secondary industries
- Safety Pharmacology (Cardio/CNS/Respiratory) (HLAGAFAB), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)
Keywords
Where Torch Biosciences is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Markets served
Torch Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Torch Biosciences product offering
Product offeringCore offering
Torch Biosciences develops next-generation AI models for predicting drug toxicity using human organoid-based biological data systems rather than animal testing. The company's core technology focuses initially on drug-induced liver injury and cardiotoxicity prediction — two leading causes of drug withdrawals — and is being advanced through the multi-institution DATAMAP project. The platform is designed to support pharmaceutical companies in reducing costly late-stage drug development failures by enabling more accurate human-relevant safety assessment.
Differentiator
Problem solved
Functional benefit
Products and services
- Drug Toxicity AI Models AI-powered drug toxicity prediction models trained on human organoid-based biological data that forecast drug-induced liver injury and cardiotoxicity in human-relevant systems, replacing traditional animal testing. Targeted at pharmaceutical companies seeking to reduce late-stage drug development failures.
Quantifiable outcome
- Addresses nearly 40% of drug withdrawals caused by drug-induced liver injury and cardiotoxicity
Companies that use Torch Biosciences
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
Torch Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Torch Biosciences partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- Inductive BiocoreInductive Bio is leading the DATAMAP project with up to $21 million in ARPA-H funding. Torch Bio is a collaborating partner in this multi-institution initiative developing AI models for drug toxicity prediction using human organoid-based systems. The project focuses on drug-induced liver injury and cardiotoxicity and involves FDA regulatory collaboration.
- AmgencoreAmgen is a pharmaceutical partner in the DATAMAP project, contributing industry expertise and planning to submit an investigational new drug (IND) application using the technology developed through the collaboration. Amgen represents a key pharmaceutical customer integrating this technology into their drug development pipeline.
- Cincinnati Children's Hospital Medical CentercoreCincinnati Children's Hospital Medical Center is an academic partner in the DATAMAP project, contributing medical research expertise to the development of drug safety testing using human organoids and AI. The institution is participating in the broader CATALYST initiative focused on enhancing drug safety studies.
- Baylor College of MedicinecoreBaylor College of Medicine is an academic partner in the DATAMAP project, collaborating on the development of AI-powered drug toxicity prediction models using advanced human model systems to improve drug safety assessment.
- U.S. Food and Drug Administration (FDA)coreThe FDA is collaborating with the DATAMAP project team to validate regulatory applications for the AI drug toxicity prediction technology. This regulatory partnership is essential for ensuring the technology meets standards required for drug development submissions and approvals.
Scale indicators2 records
Recent moves5 records
Expansion highlights5 records
Torch Biosciences competitors and assessment
Company assessmentRegional players
- XenTech (Eurofins): Specialty preclinical CRO with strong drug-induced liver injury and safety pharmacology assays, overlapping Torch Bio's primary toxicity focus areas.
Direct peers
- Emulate: Organ-on-chip and human organoid systems used to predict drug safety — directly competes on the human-model-system foundation Torch Bio's AI depends on.
- Cyprotex (Eurofins): Specialized in vitro and in silico ADME-Tox services for pharma; directly comparable as a contract predictive toxicology provider with overlapping customer base.
- Inductive Bio: Lead partner in the same DATAMAP project (2025-12-10), focused on AI-driven drug toxicity and safety prediction — directly comparable technology and customer overlap.
Emerging players
- CN Bio: Single- and multi-organ microphysiological systems for drug safety and disease modeling, overlapping in the organoid-derived human toxicity prediction stack.
Broad incumbents
- Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with ML; adjacent but broader, competing for AI-for-drug-development capital and partnerships.
- Certara: Parent of Simulations Plus and other biosimulation offerings; provides in silico toxicology, PBPK, and regulatory science tools widely used in drug safety submissions.
- Schrödinger: Established computational chemistry and predictive toxicology platform serving pharma R&D; competes for similar predictive safety budgets with a much broader software portfolio.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Torch Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Torch Biosciences leadership team
Management profileNumber of profiles
Torch Biosciences funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Torch Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Torch Biosciences
What does Torch Biosciences do?
Torch Biosciences develops next-generation AI models for predicting drug toxicity using human organoid-based biological data systems rather than animal testing. The company's core technology focuses initially on drug-induced liver injury and cardiotoxicity prediction — two leading causes of drug withdrawals — and is being advanced through the multi-institution DATAMAP project. The platform is designed to support pharmaceutical companies in reducing costly late-stage drug development failures by enabling more accurate human-relevant safety assessment.
Is Torch Biosciences a public or private company?
Torch Biosciences is a private company. It is classified as unknown and is currently operating.
When was Torch Biosciences founded?
Torch Biosciences was founded in 2016.
Where is Torch Biosciences based?
Torch Biosciences is headquartered in New York, United States, in the North America region.
Who are Torch Biosciences's main competitors?
XenTech (Eurofins) is listed as a regional player. Direct peers are Emulate, Cyprotex (Eurofins) and Inductive Bio. CN Bio is listed as an emerging player. Broad incumbents are Recursion Pharmaceuticals, Certara and Schrödinger.
Does Torch Biosciences have an API?
No public API is recorded for Torch Biosciences.
What industry is Torch Biosciences in?
Torch Biosciences's product category is AI Drug Safety Prediction. Its primary akta.pro industry code is HLAGAFAM, In Silico / Computational Toxicology & PK/PD Modeling, with a secondary code of HLAGAFAB, Safety Pharmacology (Cardio/CNS/Respiratory). Its NAICS code is 541714 and its SIC code is 8731.